Showing 2421-2430 of 2786 results for "".
- Botox Increases 20% in Italy, Non-surgical Procedures Becoming More Popularhttps://modernaesthetics.com/news/boxtox-increases-20-in-italy-non-surgical-procedures-becoming-more-popular/2473622/Botulinum toxin is becoming more and more popular in Italy. The International Society of Aesthetic Plastic Surgery’s 2023 ISAPS International Survey found there were 195,000 non-surgical aesthetics treatments with Botox, which is about 34,000 more than in 2022 and a 20% increase. I
- Study Explores Improving Neck Laxity, Wrinkle Severityhttps://modernaesthetics.com/news/ma-chief-medical-editor-leads-study-to-improve-neck-laxity-wrinkle-severity/2473621/A new case study published in Cureus by Saami Khalifian, MD; Alec D. McCarthy, MD; and Steven Yoelin, MD, investigates the efficacy and safety of an injectable therapy to treat neck wrinkles and skin laxity by utilizing a combination of hyperdiluted calcium hydroxylapatite (CaHA), platelet-r
- New Product Line for Hair, Scalp Introduced by Elevai Labs Inc.https://modernaesthetics.com/news/new-product-line-for-hair-scalp-introduced-by-elevai-labs-inc/2473616/Elevai Skincare, a subsidiary of Elevai Labs Inc., announced the Elevai S-Series, a hair and scalp product line. The three-part hair and scalp care system combines the power of exosomes with advanced mitochondrial technology. The product incorporates Elevai’s proprietary pre
- New cream targeting redness-prone skin hits markethttps://modernaesthetics.com/news/new-cream-targeting-redness-prone-skin-hits-market/2473597/Eau Thermale Avene launched its latest innovative treatment for redness-prone skin on Tuesday. The NEW! Avene Redness Expert Soothing Moisturizing Concentrated Cream targets sensitive, reactive, or intolerant skin that’s prone to redness. The cream is lightwe
- Exosome Diagnostics and Therapeutics Market Expected to Surgehttps://modernaesthetics.com/news/exosome-diagnostics-and-therapeutics-market-expected-to-surge/2473588/Emerging potential of exosome-based liquid biopsy is a primary factor driving the growth of the market. The Exosome Diagnostics and Therapeutics market is expected to surge from $59 million in 2024 to $6.848 billion by 2032 with a compound annual growth rate of 108.9%. The exosome
- Top Plastic Surgeon Leads Study on Stackable Medical Grade Skincarehttps://modernaesthetics.com/news/top-plastic-surgeon-leads-study-stackable-medical-grade-skincare/2473587/A new study in the Aesthetic Surgery Journal led by Few, MD, shows positive results for using a stackable skincare routine. The use of stackable skincare can help streamline patients to treat primary concerns without causing irritation that can sometimes come from patients layerin
- Men’s skincare market expected to grow by more than $6Bhttps://modernaesthetics.com/news/mens-skincare-market-expected-grow-more-than-6-billion/2473585/Skincare products targeted for men are generating massive attention and new market research estimates the market will grow by more than $6 billion over the next four years. Technavio reports a CAGR of about 7.19% from 2024 to 2028. Industry leaders are catering to t
- Bovine Colostrum Trend Going Viralhttps://modernaesthetics.com/news/bovine-colostrum-trend-going-viral/2473580/Is colostrum the new collagen? That is the question posed in a new Marie Claire article examining the social media trend of using bovine colostrum in the pursuit of bright skin, lustrous hair, and bloat-less midsections. A TikTok search for “colostrum” yielded more
- Dr. Jeanine Downie Discusses Fake Botox in TV Segmenthttps://modernaesthetics.com/news/dr-jeanine-downie-discusses-fake-botox-in-tv-segment/2473578/If public awareness is the key to combatting the counterfeit Botox problem that has been popping up around the country recently, then Modern Aesthetics Editorial Board member Jeanine B. Downie, MD, FAAD, took a big step May 13. Dr. Downie joined anchor Vanessa Freeman on P
- FDA Clears New Indication for UltraClear Laserhttps://modernaesthetics.com/news/fda-clears-new-indication-for-ultraclear-laser/2473577/The U.S. Food and Drug Administration (FDA) cleared a new indication of Acclaro Medical's UltraClear® cold ablative fractional 2910 nm fiber laser, expanding the use of the technology for the treatment of benign pigmented lesions and vascular dyschromia, the company announced i